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84Objective: Transcatheter aortic valve implantation is a newmethod for treatment of very high-risk patients with
aortic valve stenosis. Especially in patients who have had previous cardiac surgery, the operative risk can be re-
duced. Nevertheless, this new procedure has some potential risks in patients with previous mitral valve surgery,
owing to the increased risk by direct contact between the 2 valves with inhibition of mechanical mitral leaflet
mobility, in view of potential mitral annulus pressure or leaflet damage caused by transcatheter wires.
Methods: Between April 2008 and April 2010, 217 consecutive patients (mean EuroSCORE: 40%  20%;
mean Society of Thoracic Surgeons mortality score: 21  17%; mean age: 79  9 years, 67 men, 150 women)
underwent transapical aortic valve implantation. In 6 patients a previous mitral operation (1 valve reconstruc-
tion, 5 valve replacements) had been performed.
Results: In all 6 patients the aortic valve could be implanted by the transapical approach, and the procedure was
successful. In 2 patients the heart–lung machine was used electively owing to low ejection fraction (10% and
15%). In 2 patients there was slight paravalvular leakage of the aortic prosthesis. Neither increased mitral valve
regurgitation nor mitral leaflet damage was observed. One patient had endocarditis develop 8 months postoper-
atively and another with severe reduced left ventricular function died early postoperatively.
Conclusions: Transcatheter valve implantation can be performed successfully after previous mitral valve
surgery. Particular care should be taken to achieve optimal valve positioning and not to damage mitral leaflets
during manipulation with guide wires. (J Thorac Cardiovasc Surg 2011;142:84-8)Transapical aortic valve implantation is a new method that
might reduce the risk of conventional surgical aortic valve
replacement in very high-risk patients.1,2 Especially in
patients with previous cardiac surgery, the operative risk
can be reduced inasmuch as there is less surgical trauma.
Nevertheless, previous mitral valve replacement is
classified as a contraindication for implantation of the
Edwards SAPIEN valve by the manufacturing company
(Edwards Lifesciences, Irvine, Calif). Some potential risks
exist in patients with previous mitral valve surgery owing
to increased risk of endocarditis, potential mitral annulus
pressure caused by aortic valve stent dilatation, increased
risk of paravalvular leakage owing to asymmetric stent
dilatation, the possibility of Edwards SAPIEN valve
dislocation owing to poor stent anchorage, direct contact
between the 2 valves with inhibition of mechanical mitral
leaflet mobility, or biological leaflet damage caused by
transcatheter wires.eutsches Herzzentrum Berlin, Berlin, Germany.
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The Journal of Thoracic and Cardiovascular SurgeIn this study, we examine the surgical procedure and the
postoperative course of patients undergoing transcatheter
aortic valve implantation after previous mitral valve surgery
and discuss the potential risks.
METHODS
Transapical aortic valve implantation was performed between April
2008 and April 2010 in 217 patients at the Deutsches Herzzentrum Berlin.
In 41 patients the procedure was performed as a reoperation: in 32 after
previous coronary artery bypass grafting, in 12 after previous aortic valve
replacement, and in 6 patients after mitral valve surgery. Of these 6 pa-
tients, 1 had had mitral valve reconstruction (with Carpentier ring implan-
tation), and 5 patients had had previous mitral valve replacement: St Jude
Medical 29 mm (St Jude Medical, Inc, St Paul, Minn), Hancock 33 mm,
29 mm, and 31 mm (Medtronic, Inc, Minneapolis, Minn), and Bjo¨rk–
Shiley 29 mm (Shiley, Inc, Irvine, Calif) (Table 1).
In all 6 patients, owing to their increased risk for conventional surgery,
transapical aortic valve implantation was done using a biological Edwards
SAPIEN valve. The procedures were performed in a hybrid operating room
in a completely sterile environment and under fluoroscopic imaging with
a monoplane angiography system. The surgical technique of transcatheter
valve implantation was based on the procedure described by Walther and
associates1,2 with the modification of transcatheter valve positioning and
liberation under simultaneous angiography with contrast medium, not
only to make a blind technique visible, but also to find optimal position
and to reduce the risk of paravalvular leakage.3 Primarily, the intraopera-
tive transesophageal echocardiographic examination was used to control
mitral leaflet mobility and ventricular function and to evaluate potential
valvular and paravalvular leakage of the Edwards SAPIEN valve. Two
patients received 23-mm Edwards SAPIEN valves and the other 4 patients,
26-mm valves. The preoperative and postoperative examinations included
clinical and laboratory examinations, electrocardiography, chestry c July 2011
Abbreviations and Acronyms
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
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STS ¼ Society of Thoracic Surgeons
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phy, and computed tomography of the chest and pelvis. Preoperative
coronary angiography and ultrasound examinations (Doppler) of the
arteries and veins of the lower extremities and of the carotid arteries
were performed.
RESULTS
In all 6 patients the technical procedure was performed
using the standard technique.1,3
Mitral Valve Reconstruction
One patient had had previous mitral valve reconstruction
with ring implantation.
Patient 1. In August 2008, an 82-year-old woman was
admitted with severe comorbidities (chronic obstructive
lung disease, kidney dysfunction, insulin-dependent diabe-
tes type II, and severe peripheral arteriosclerosis). She had
a European System for Cardiac Operative Risk Evaluation
(EuroSCORE) of 45% and a Society of Thoracic Surgeons
(STS) mortality score of 23%. A Carpentier–Edwards
Physio ring (Edwards Lifesciences) had been implanted
for severe mitral valve regurgitation 20 years earlier. The
echocardiographic examination showed good left ventricu-
lar function, mitral valve regurgitation of grade II, and
severe aortic valve stenosis without regurgitation. Owing
to severe arteriosclerosis of the peripheral vessels, transap-
ical implantation of a 23-mm Edwards SAPIEN valve was
performed. The postoperative echocardiographic check
showed good prosthetic function without insufficiency.
Eight months later, aortic valve endocarditis developed.
The patient required a reoperation, had postoperative
pneumonia, and died 4 weeks later of multiorgan failure
(Table 1).
Mitral Valve Replacement
Five patients had had previous mitral valve replacement.
Patient 2. We were faced in October 2008 with the case of
a 37-year-old woman with severe familial cholesterolemia
type II a. She had had a portocaval shunt since 1976, serious
calcification of the vessels, and implantation of an apico-
descending conduit in May 2004 (owing to severe aortic
valve calcification and porcelain aorta). Mitral valve re-
placement with a mechanical prosthesis (St Jude Medical,
29 mm) was performed in February 2004. On admission,
the native aortic valve showed severe insufficiency (grade
II–III, New York Heart Association classification IV, Euro-The Journal of Thoracic and CSCORE 85%, STS mortality score 75%), leading to global
left ventricular failure (ejection fraction 10%). The situa-
tion was first evaluated by our staff and then discussed
with the patient’s family. Conventional aortic valve replace-
ment was abandoned owing to porcelain aorta, and the
decision was made in favor of transapical implantation of
a 23-mm Edwards SAPIEN valve through the apico-
descending conduit as a last resort. The procedure was per-
formed using the heart–lung machine with femoro-femoral
cannulation. Postoperative echocardiographic examination
confirmed correct aortic valve function (paravalvular valve
insufficiency grade I) and good mitral prosthesis function,
but severe left ventricular failure remained (ejection frac-
tion 10%). Owing to the still affected left side of the heart,
an extracorporeal membrane oxygenator was connected.
Unfortunately, the heart function did not recover and the
patient died 5 days later of septicemia (Table 1).
Patient 3. In January 2009 we accepted a 75-year-old man
with a history of endocarditis. He had had aortic homo-
graft implantation 13 years earlier and mitral valve re-
placement with a Hancock 33-mm biological valve 2
years earlier. Echocardiographic examination showed no
signs of endocarditis; nevertheless, homograft degenera-
tion with insufficiency of grade II–III was seen. There
was no impairment of mitral prosthesis function, but se-
vere left ventricular failure (ejection fraction 15%). The
patient had multiple comorbidities (pulmonary hyperten-
sion, atrial fibrillation, kidney failure, hyperlipoproteine-
mia, and hypertension). The EuroSCORE was 89% and
the STS mortality score 42%. Owing to severe peripheral
arteriosclerosis, transapical implantation of a 26-mm Ed-
wards SAPIEN valve was performed. Because of impaired
left ventricular function, the heart–lung machine with
femoro-femoral cannulation was used. The procedure
was technically uncomplicated. Echocardiographic check
showed good aortic valve function without insufficiency
and an unhindered mitral prosthesis. The patient was extu-
bated on the following day and was discharged 22 days
later. Today, 1 year later, the patient has recovered ventric-
ular and good aortic and mitral valve function (Table 1).
Patient 4. The fourth patient with a history of mitral valve
replacement was treated in November 2008. The 80-year-
old woman with multiple morbidities had a EuroSCORE
of 41% and an STSmortality score of 36%. In 1987 the mi-
tral valvewas replaced by a Hancock 29-mm prosthesis and,
owing to valve degeneration, a second valve replacement
(31 mm) was performed in 1997 (Figure 1). On this admis-
sion, she had severe aortic valve stenosis with slight regur-
gitation (grade I). The mitral prosthesis was not impaired.
The left ventricular function was slightly reduced (ejection
fraction 35%, left ventricular end-diastolic diameter 56
mm). Inasmuch as the iliac artery was small and showed
local calcification, transapical implantation of an Edwards
SAPIEN valve (26 mm) was performed and a coronary stentardiovascular Surgery c Volume 142, Number 1 85
TABLE 1. Patients with previous mitral valve surgery
Number of patient 1 2 3 4 5 6
Sex (male/female) Female Female Male Female Female Female
Age (y) 82 37 75 80 82 85
Weight (kg) 61 67 58 56 72 59
NYHA class* III IV III III III IV
FEV (L/100 mL) 1.03 / 62 —* 1.4 / 53 1.19 / 77 1.19 / 59 1.49 / 68
EuroSCORE (%) 45 85 89 41 65 45
STS mortality score (%) 23 75 42 36 50 32
Previous mitral valve
reconstruction/replacement
CE Physio ring SJM (29 mm) Hancock (33 mm) Hancock (31 mm) Hancock (31 mm) BS (29 mm)
Echocardiographic data
LV end-diastolic diameter (mm) 57 59 60 56 41 45
LV ejection fraction (%) 60 10 15 35 50 50
Mitral valve
Mitral valve insufficiency (grade) II < I < I I 0 < I
Aortic valve
Aortic valve insufficiency (grade) 0 II–III II–III I 0 I
Aortic valve gradient (max/mean [mm Hg]) 100/70 50/40 20/10 96/60 60/50 80/54
Aortic valve orifice area (cm2) 0.45 0.7 0.8 0.6 0.7 0.6
Diameter of aortic annulus (mm) 22 18 22 21 23 20.5
NYHA,NewYork Heart Association; FEV, forced expiratory volume; EuroSCORE, European System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic Surgeons;
LV, left ventricular; CE, Carpentier–Edwards; SJM, St Jude Medical; BS, Bjo¨rk–Shiley. *Measurement not possible owing to cardiogenic shock.
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eration was performed without the heart–lung machine. The
patient was extubated 17 hours later and the postoperative
course was uneventful. Echocardiographic examination
showed correct prosthetic function without insufficiency.
She was discharged on day 20, and 14 months later she still
has good aortic and mitral valve prosthesis function
(Table 1).
Patient 5. The fifth patient, an 82-year-old woman, had
had an urgent coronary artery bypass graft operation and bi-
ological mitral valve replacement using a 31-mm Hancock
II prosthesis 4 years earlier. In January 2010 she had severe
aortic valve stenosis and severe symmetric calcification.
The EuroSCORE was 65% and the STS mortality score
50%. An Edwards SAPIEN valve (23 mm) was implanted
transapically without the heart–lung machine. She was ex-
tubated 1 hour after the operation. The postoperative echo-
cardiographic examination showed correct mitral and aortic
valve function; the Edwards SAPIEN valve had slight para-
valvular regurgitation (less than grade I). The following
course was uneventful (Table 1).
Patient 6. The last patient (female, 85 years old) had had
a mechanical mitral valve replacement (Bjo¨rk–Shiley) 16
years earlier (Figure 2). She was admitted in March 2010
with dyspnea (New York Heart Association classification
IV, EuroSCORE 45%, STS mortality score 32%),4 and
transthoracic and transesophageal echocardiography
confirmed the diagnosis of a severe aortic valve stenosis
combined with small valve regurgitation (grade I). The
ejection fraction was good (50%), and the mitral valve86 The Journal of Thoracic and Cardiovascular Surgeshowed good function without stenosis or significant insuf-
ficiency (<grade I). The diameter of the aortic valve annulus
was 20.5 mm. Owing to symmetric calcification of the 3
aortic valve leaflets, a biological Edwards SAPIEN valve
(23 mm) could be implanted. The iliac arteries were too
small for transfemoral access, and a transapical technique
was chosen. During introduction of the 26F transapical
valve delivery system (Edwards) into the outflow tract of
the left ventricle to avoid touching the mitral prosthesis
with the crimped valve, the leaflet of the mitral prosthesis
was touched by the delivery system, inhibiting its mobility.
This made immediate retraction of the delivery system nec-
essary. The remainder of the procedure was uneventful and
the patient was extubated 6 hours after the operation. The
postoperative echocardiographic examination showed
good prosthetic function with minimal central leakage
(<grade I) and still good mitral valve function. The patient
left the hospital on the 27th postoperative day. Today,
2 months after the operation, she is well, with good aortic
and mitral valve function (Table 1).
DISCUSSION
In patients with previous sternotomy, the operative risk is
elevated during conventional aortic valve replacement. The
mortality ranged from 3% to 26%.5,6 Although in newer
publications a lower mortality risk has been described,7
this problem still exists, especially in patients with ad-
vanced age and increased STS and EuroSCORE.
Transcatheter aortic valve implantation has been intro-
duced to reduce the surgical risk. Nevertheless, previousry c July 2011
FIGURE 2. Fluoroscopy after transapical valve implantation with Bjo¨rk–
Shiley valve (29 mm) in the mitral valve position (patient 6).
FIGURE 1. Fluoroscopy after transapical valve implantation with Han-
cock valve (31 mm) in the mitral valve position (patient 4).
Drews et al Acquired Cardiovascular Disease
A
C
Dmitral valve replacement is classified as a contraindication
for Edwards SAPIEN valve implantation by the manufac-
turer. This can be explained by several factors: the in-
creased risk of endocarditis, the potential mitral annulus
pressure caused by aortic valve stent dilatation, increased
risk of paravalvular leakage owing to asymmetric stent di-
latation, the possibility of Edwards SAPIEN valve disloca-
tion owing to unsatisfactory stent anchorage, the potential
direct contact between the 2 valves with inhibition of me-
chanical mitral leaflet mobility, and the danger of biologi-
cal leaflet damage being caused by transcatheter wires. The
experience using the transcatheter technique for aortic
valve implantation in patients with previous mitral valve
surgery is still limited. Recently, a report of retrograde im-
plantation of CoreValve aortic prostheses (CoreValve Inc,
Irvine, Calif) in 4 patients with previous mitral valve re-
placement was published.8 Additionally, a case report on
an 84-year-old woman with previous mechanical bileaflet
mitral valve replacement showed the surgical feasibility
of transapical implantation of the Edwards SAPIEN valve.9
In this report, the authors recommended higher positioning
of the aortic prosthesis.
Our experience consists of 6 patients with different tech-
niques of previous mitral valve surgery. We show that
transcatheter wires should be introduced carefully so as
not to touch the mitral prosthesis. The 26F transapical
valve delivery system (Edwards) should not be introduced
into the outflow tract of the left ventricle to avoid touching
the mitral prosthesis. Additionally, transcatheter valve po-
sitioning and liberation should be done in all cases underThe Journal of Thoracic and Csimultaneous angiography with contrast medium, not
only to make a blind technique visible, but also to find
optimal position and to reduce the risk of paravalvular
leakage3 and contact with the mitral prosthesis. Valve
dislocation or increased paravalvular leakage was not
observed.
In 1 patient with previous mitral valve reconstruction
using a ring implantation, endocarditis occurred postopera-
tively, making reoperation necessary. The rate of endocardi-
tis in patients with combined aortic and mitral valve surgery
is still elevated, making effective prophylaxis for endocar-
ditis necessary.10CONCLUSIONS
Previous sternotomy is still an increased risk for second-
ary valve surgery. Transapical aortic valve implantation in
patients with previous heart surgery has been in practical
use for 2 years, so that this report reflects the early experi-
ence. Nevertheless, high-risk patients with previous mitral
valve surgery needing aortic valve replacement seem to
be optimal candidates for transcatheter valve implantation.
With careful introduction of the transcatheter wires under
fluoroscopic and echocardiographic control and liberation
of the Edwards SAPIEN valve using the ‘‘Berlin addition,’’3
transapical valve implantation can be safely performed after
previous mitral valve surgery, and this should no longer be
regarded as a contraindication.
We thank Ms Anne Gale, Editor in the Life Sciences, for edito-
rial assistance.ardiovascular Surgery c Volume 142, Number 1 87
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